Production and purification of pM766 gp160 V1, pSW gp120 V1, and SIV p57 Gag custom DNA plasmids.

National Cancer Institute (NCI), Center for Cancer Research (CCR), Vaccine Branch (VB) and Animal Models & Retroviral Vaccines Section (AMRVS) plans to procure, on a sole source basis, Production and purification of pM766 gp160 V1, pSW gp120 V1, and SIV p57 Gag custom DNA plasmids from Aldevron LLC of 4837 Amber Valley Pkwy S, Fargo, ND 58104.

This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1 (b)(1)(i) using simplified acquisition procedures for commercial acquisitions. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees. Commercial terms and conditions, FAR 52.212-4 and 52.212-5, shall apply to any acquisition related to this notice. FAR 52.202-24 and FAR 52.202-25 are also applicable.

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Vaccine Branch (VB) and Animal Models & Retroviral Vaccines Section (AMRVS) requires the production, transformation, growth, and purification of plasmid DNA isolated from SIV for the express purpose of use in animal studies involving non-human primates. NCI requires a Contractor with expertise in producing large quantities of purified plasmids isolated from monoclonal antibody structures.

The intent of this requirement is production, transformation, growth, and purification of plasmid DNA isolated from SIV for the express purpose of use in animal studies involving non-human primates. The Contractor shall 1.) provide 600mg of purified pM766 gp160 V1 custom plasmid, 2.) provide 40mg of purified pSW M766 gp120 V1 custom plasmid, 3.) provide 600mg of purified SIV p57 Gag custom plasmid, 4.) perform research-grade sequencing, and 5.) perform SYBR Gold Staining on Agarose gel for residual RNA detection.

Aldevron has produced the required plasmids for the Animal Models & Retroviral Vaccines Section (AMRVS) lab for on-going research efforts. Using another source could introduce variables that would jeopardize research efforts. To maintain continuity in the lab's on-going research, the required plasmids must come from the same source. For these reasons, Aldevron LLC is the sole known source capable of fulfilling NCI's requirements.

This notice is not a request for competitive quotation. However, if any interested party, especially small business believes it can meet the above requirement, it may submit a capability statement for the Government to consider. The response and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 12:00 PM ET, on August 23, 2019. All responses and questions must be via email to Miguel Diaz, Contracting Officer at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered and have valid certification through SAM.GOV and have Representations and Certifications filled out. Reference: 75N91019Q00145 on all correspondence.

.